The purpose of this study is to assess the effects of a single infusion of ketamine for adolescents and young adults with obsessive-compulsive disorder (OCD). Ketamine is a FDA-approved anesthetic medication that can possibly cause a rapid decrease in OCD symptoms. To be eligible to participate, patients need to have already tried at least one SRI…
The Center for OCD and Related Disorders is currently conducting a study in treating Obsessive-compulsive Disorder (OCD), which is a severe illness characterized by distressing intrusive thoughts, images, or impulses about a variety of themes (e.g., fears of contamination or harm) and repetitive…
This study is investigating how the brains of people with OCD may change with treatment. The study uses Magnetic Resonance Imaging (MRI) to scan the brain, and the treatment used is a form of Cognitive-Behavioral therapy consisting of Exposure and Ritual Prevention (EX/RP). Participants will undergo a scan, which lasts for approximately 2 hours and takes…
The Center for OCD and Related Disorders at New York State Psychiatric Institute/Columbia University Medical Center is seeking individuals aged 18+ with obsessive-compulsive disorder (OCD) to participate in a survey regarding their experiences with marijuana/cannabis. We hope this study will lead to increased understanding of…
The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients enrolled in the study will smoke marijuana containing different concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on the brain…
Early Age-Related Hearing Loss Investigation (EARHLI) is a study to obtain information on how a hearing aid-based intervention can prevent cognitive decline in those at risk for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). Age-related hearing loss (ARHL) is the third most common chronic condition in older adults. The…
This is a 22-week treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 2 study to evaluate the efficacy, safety, and tolerability of the study drug E2027, in participants with Dementia with Lewy Bodies (DLB) Lewy Body Dementia - LBD. The main purpose of this research study is to find if a new drug called E2027 works in people who…
This study is of a drug called CT1812, that is being evaluated as a possible treatment for Dementia with Lewy Bodies. In this study, which is carried out at multiple sites in the country, participants receive either CT1812 at one of two doses or placebo. The duration of the study is up to about 35 weeks. Participants receive blood tests, cerebrospinal fluid…
A significant focus of healthcare research is aimed at biomarker discoveries in brain and heart diseases in particular, and their impact on the human body in general. MRI is a key component in these healthcare services. It provides a non-invasive and non-ionizing approach to diagnose pathologies along with significant internal and external contrast…